Related Experiment Video
Updated: Nov 7, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
COVID-19 Presentation in Patients with Sickle Cell Disease: A Case Series
Amber Chen-Goodspeed1, Modupe Idowu2
1University of Texas McGovern School of Medicine, Houston, TX, USA.
Insights
Sickle cell disease (SCD) patients with COVID-19 may not show typical symptoms. Instead, they often present with vaso-occlusive crisis (VOC), necessitating prompt COVID-19 testing for early intervention.
Area of Science:
- Hematology
- Infectious Diseases
- Public Health
Background:
- COVID-19 (caused by SARS-CoV-2) severity is influenced by comorbid health conditions.
- Sickle cell disease (SCD) is a hematological condition recognized as a potential comorbidity.
- Understanding COVID-19's impact on SCD patients is crucial for public health management.
Observation:
- A case series involving 5 patients with SCD who contracted SARS-CoV-2 in 2020 was examined.
- Observed COVID-19 severity ranged from mild symptoms to severe illness requiring hospitalization and blood transfusions.
- A significant finding was that 4 out of 5 patients presented with symptoms mimicking vaso-occlusive crisis (VOC) rather than the classic COVID-19 triad.
Findings:
- Patients with SCD and COVID-19 may not exhibit the typical cough, shortness of breath, and fever.
- Vaso-occlusive crisis (VOC) symptoms, such as severe pain, were common presentations in SCD patients with COVID-19.
- COVID-19 may trigger inflammatory cytokines (e.g., IL-6), leading to systemic inflammation and red blood cell sickling.
Implications:
- Prompt COVID-19 testing is recommended for SCD patients presenting with VOC and potential SARS-CoV-2 exposure.
- Early diagnosis and tailored treatment can reduce mortality and morbidity in this high-risk population.
- Further research is needed to fully elucidate the complex interactions between COVID-19 and sickle cell disease.
Abstract:
BACKGROUND Certain health conditions have been proven to have an effect on the severity of COVID-19, the disease caused by SAR-COV-2. The list of identified comorbid conditions includes hematological diseases, with sickle cell disease (SCD) falling into this category. CASE REPORT This case series examines the history, presentation, and clinical course of 5 patients with SCD who tested positive for SAR-COV-2 during the spring and summer of 2020. These patients experienced COVID-19 severities ranging from a mild cough and congestion to 8-day hospitalizations requiring blood transfusions. CONCLUSIONS While there is still a great amount of research on the interaction between COVID-19 and SCD needed, from this study we have concluded that patients with SCD do not always present with the classic COVID-19 triad of cough, shortness of breath, and fever. Often, these patients present with symptoms of vaso-occlusive crisis (VOC), including severe leg, flank, and chest pain, as was seen in 4 of 5 of our patients. We, and several other researchers, believe that this association between COVID-19 and VOC could be due to COVID-19 triggering inflammatory cytokines (notably IL-6) leading to system-wide inflammation, which induces sickling of the red blood cells. Based on this report, we recommend that SCD patients presenting with VOC who have had exposure to SAR-COV-2 be promptly tested for SAR-COV-2 to guide treatment and reduce mortality and morbidity in this vulnerable population.
More Related Videos
08:23Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017